Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Who's Winning the Biosimilars Race?

1,478 views

Published on

With the first biosimilar approved in the US, pharmaceutical companies are scrambling to bring the next to market. Which company is in the lead?

Published in: Healthcare
  • Be the first to comment

Who's Winning the Biosimilars Race?

  1. 1. Who’s Leading the Biosimilars Race? Powered by Small World Social www.biolink.us
  2. 2. Powered by Small World Social With the first biosimilar approved in the US, pharmaceutical companies are scrambling to bring the next to market. US biopharma giants, Pfizer and Amgen, along with South Korea’s Celltrion and Swiss based Novartis are emerging as frontrunners in the biosimilars race. Biolink.us
  3. 3. Powered by Small World Social Celltrion has led the pack until now, with seven molecules in the development stage, plus biosimilars of Humira, Rituxan, Herceptin and Avastin already in clinical trials through its pre- existing agreement with biosimilar innovator Hospira. It’s also pushing for FDA approval of its copy of Johnson & Johnson/Merck’s rheumatoid arthritis drug, Remicade, which it currently sells in Europe as Remsima. Celltrion hopes to launch it on the US market later this year, under the name, Inflectra. Biolink.us
  4. 4. Powered by Small World Social However, Pfizer’s $17 billion acquisition of Hospira in February may present another hurdle for Celltrion, with Hospira’s five biosimilars in development bumping up Pfizer’s stable to ten. Biolink.us
  5. 5. Powered by Small World Social Amgen took the first hit to its market position when Sandoz/Novartis copied its originator, Neupogen with Zarxio. Sandoz is also seeking FDA approval of another two Amgen drugs, Neulasta, which like Zarxio boosts white blood cell counts, and Enbrel, another rheumatoid arthritis drug. Pfizer/Hospira has been circling, with Retatcrit, its version of Amgen's anemia biologic, Epogen. Available in Europe since 2008, it is currently awaiting FDA approval. This adds up to almost $11 billion worth of US sales for Amgen’s four originator biologics in 2014, according to the company’s financial statements Biolink.us
  6. 6. Powered by Small World Social But Amgen is showing plenty of fight for market share. Working on nine biosimilar copies of competitors' drugs, it aims to get the first to market by 2017 and another four by 2019. That’s estimated at a combined $52 billion worth of sales according to last year’s figures. Biolink.us
  7. 7. Powered by Small World Social Amgen, Pfizer, Novartis, and Celltrion are wisely playing both sides of field – capitalizing on the new biosimilars market, while continuing to develop original biologics. And with such a tightly-run race, it will be interesting to see who comes out on top by year’s end. From this article on BioLink: https://biolink.smallworldsocial.com/portal#/?id =55354099c4d7d532fdbdc48e Biolink.us
  8. 8. Visit https://biolink.us to get the latest in biosimilar news curated from around the world Powered by Small World Social www.biolink.us Want to read more about biosimilars?

×